Latest news stories about centronuclear and myotubular myopathy can be found on this page. To see news stories from previous years please see the News archive pages.
- Astellas, Audentes pen $3bn gene therapy deal
PharmaTimes, 6 December - Astellas doubles down on gene therapy with $3bn Audentes deal
Life Sciences Intellectual Property Review, 5 December 2019 - Astellas makes gene therapy a core focus with $3bn Audentes buy
- PMLive, 5 December 2019
- Audentes in $3bn gene therapy acquistion, highlights manufacturing capabilities
BioPharma, 4 December 2019 - Astellas enters into definitive agreement to acquire Audentes Therapeutics
European Phbarmaceutical Review, 4 December 2019 - Gene Therapies Get a $3 Billion Vote of Confidence
Washington Post, 4 December 2019 - Astellas: Large-scale gene therapy plant major driver in $3bn Audentes deal
BioProcess International, 4 December 2019 - Astellas Bets On Gene Therapy With $3B Audentes Acquisition Offer
Exome, 3 December 2019 - Japan’s Astellas to buy Audentes for $3 billion in high-priced gene therapy bet
Reuters, 2 December 2019 - Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics
Audentes, 2 December 2019 - Dynacure’s Chief Scientific Officer, Dr. Belinda Cowling, Receives Irène Joliot-Curie Prize for Women in Business and Technology
Dynacure, 27 November 2019 - Targeted Genetic Screening Useful in Diagnosing Patients with SMA-like Symptoms
22 November 2019 - A little superhero
La Region, 21 November 2019 - Centronuclear Myopathies Drug Market Analysis with Future Prospects to 2026 | Audentes Therapeutics, Ionis Pharmaceuticals, Inc, Dynacure, Valerion Therapeutics
Herald Correspondent, 15 November 2019 - Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Audentes, 11 November 2019 - Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
BusinessWire, 7 November 2019 - New University of Washington Center to Produce Stem Cells for Research on Muscle Disorders Such as ALS
ALS News Today, 21 October 2019 - A rare opportunity to study genetic disorders: Mayo Clinic graduate research
University of Wisconsin-Eau Claire, 18 October 2019 - New research center to explore muscle health and disease
NewsWise, 17 October 2019 - Toni’s sunflowers sow the seeds of success
Liverpool Echo, 16 October 2019 - New research center to explore muscle health and disease
UW Medicine, 14 October 2019 - Audentes Therapeutics (BOLD) Announces Positive AT132 Trial Data
StreetInsider, 7 October 2019 - Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society
Audentes, 5 October 2019 - Dynacure Presents New Preclinical Results on Muscle Targeting with Antisense Oligonucleotides at the 24th Annual International Congress of the World Muscle Society
Dynacure, 2 October 2019 - Building A $1 Billion Gene Therapy Company — In 6 Years
lifescienceleader.com, 1 October 2019 - Audentes Therapeutics to participate in upcoming investor conference
Audentes, 1 October 2019 - Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM)
Audentes, 30 September 2019 - High school was hard, then Farmington football captains ‘changed senior year’
Twincities.com, 27 September 2019 - Remembering young Jack at charity golf day
Worthing Herald, 13 August 2019 - Dynacure Receives Orphan Drug Designation for DYN101 for the Treatment of Centronuclear Myopathies
BioPharma Global, 12 August 2019 - Investigational Antisense Medicine Gets Orphan Drug Status for Centronuclear Myopathies
empr.com, 9 August 2019 - Dynacure Receives Orphan Drug Designation from the US FDA for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’
Dynacure, 8 August 2019 - Dynacure Receives Orphan Drug Designation in the EU for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’
Dynacure, 11 July 2019 - Genethon emphasizes its decisive role in the first gene therapy for a neuromuscular disease
EurekAlert, 27 May 2019 - Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Benzinga, 7 May 2019 - Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Audentes, 7 May 2019 - Highlights: American Society of Gene and Cell Therapy Meeting
BioSpace, 3 May 2019 - Audentes exhibits new positive data from the ASPIRO clinical trial
ReportsGo, 3 May 2019 - Boys with a rare muscle disease are breathing on their own, thanks to gene therapy
Science, 2 May 2019 - Dynacure declares the Approval of Clinical Trial Submission for DYN101
A Market Journal, 2 May 2019 - Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy
Yahoo Finance, 1 May 2019 - Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy
PR Newswire, 1 May 2019 - Dynacure Announces Approval of Clinical Trial Application for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’
PipelineReview, 30 April 2019 - Dynacure Announces Approval of Clinical Trial Application for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’
Yahoo Finance, 30 April 2019 - Dynacure Announces Approval of Clinical Trial Application for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’
PR Newswire, 30 April 2019 - Audentes Launches Internal cGMP Plasmid Manufacturing Facility
Genetic Engineering and Biotechnology News, 26 April 2019 - Dynacure receives Research Grant from the Programme d’Investissements d’Avenir (PIA3) Grand Est operated by Bpifrance to Expand Development of Lead Antisense Program Dyn101 for Rare Disease ‘Centro Nuclear Myopathies’ (CNM)
Dynacure, 25 April 2019 - Alfred J. Spiro
The Suffolk Times, 23 April 2019 - Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility
PR Newswire, 23 April 2019 - Biopsy determines centronuclear myopathy in a 46 year old patient
Femexer, 17 April 2019 - Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
Pharmiweb, 15 April 2019 - Audentes Therapeutics Recognizes Rare Disease Day by Launching “Be Bold for Courageous Patients” Program to Support Patients Living with Rare Diseases
Audentes, 28 February 2019 - Audentes Therapeutics reports fourth quarter 2018 and full year financial results and provides corporate update
Audentes, 27 February 2019 - This Guy Has Had to Literally Fight for His Life: Here He Is Singing Fight Song
We Heart It, 18 February 2019 - Dream comes true for a young P.K. Subban fan in Nashville
Montreal Gazette, 14 February 2019 - Breast cancer drug may help treat muscle paralysis
Medical News Bulletin, 4 February 2019 - Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation
PR Newswire, 31 January 2019 - New online patient education program on gene and cell therapies launched
SMA News Today, 25 January 2019 - Audentes Therapeutices Inc, (NASDAQ:BOLD) gives an update on its recent progress and strategic priorities for 2019
FDA Headlines, 24 January 2019
